Abbott and AstraZeneca announced today a collaboration to co-develop and market a combination treatment that will target all three important blood lipids — LDL-C "bad" cholesterol, HDL-C "good" cholesterol, and triglycerides — in one single pill as part of a comprehensive treatment regimen. Under the agreement, the companies will initiate two parallel programs: a CRESTOR (rosuvastatin calcium)/TriCor (fenofibrate tablets) fixed-dose combination and a CRESTOR/ABT-335 combination. ABT-335 is Abbott's proprietary next-generation fenofibrate currently in Phase III clinical trials.
PR Newswire
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Dialogue’s Triage Support Technology Earns CE Mark
Artificial intelligence is “an important asset to reduce human bias when medical professionals triage patients in emergency rooms,” the company said.
Woodcock to Congress: U.S. Must Revamp Manufacturing to Spur API Production
Only 28 percent of facilities making APIs for the U.S. market are domestic.
FDAnews Drug Daily Bulletin
ABBOTT AND ASTRAZENECA ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE CRESTOR AND NEXT-GENERATION TRICOR FIXED-DOSE COMBINATION
July 6, 2006
